Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Invested Capital (2017 - 2025)

Avalo Therapeutics filings provide 9 years of Return on Invested Capital readings, the most recent being 0.01% for Q4 2025.

  • On a quarterly basis, Return on Invested Capital changed 0.0% to 0.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 0.0% change, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Invested Capital hit 0.01% in Q4 2025 for Avalo Therapeutics, down from 0.01% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.12% in Q3 2022 to a low of 3.43% in Q2 2022.
  • Median Return on Invested Capital over the past 5 years was 0.01% (2024), compared with a mean of 0.18%.
  • Biggest five-year swings in Return on Invested Capital: plummeted -340bps in 2022 and later soared 346bps in 2023.
  • Avalo Therapeutics' Return on Invested Capital stood at 0.03% in 2021, then soared by 324bps to 0.06% in 2022, then crashed by -143bps to 0.02% in 2023, then soared by 64bps to 0.01% in 2024, then rose by 6bps to 0.01% in 2025.
  • The last three reported values for Return on Invested Capital were 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025) per Business Quant data.